Rogerio Vivaldi, Sigilon CEO (via website)
March 15, 2023 07:29 AM EDTUpdated March 17, 06:11 PM
R&D
Cell/Gene Tx

Sig­ilon fo­cus­es on type 1 di­a­betes, re­duces spend on MPS-1 af­ter let­ting CMO go (cor­rect­ed)

Kyle LaHucik

Senior Reporter

Sig­ilon Ther­a­peu­tics said it de­creased ex­ter­nal spend on a rare lyso­so­mal stor­age dis­or­der as the Bob Langer-found­ed biotech fo­cus­es its cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times